(Q44199963)

30 November 2017

title

Letrozole's superiority over progestins and tamoxifen challenges standards of care in endocrine therapy for metastatic breast cancer (English)

1 reference

30 November 2017

1 reference

2

1 reference

30 November 2017

Piccart MJ

1

1 reference

30 November 2017

Atalay G

series ordinal

3

1 reference

30 November 2017

language of work or name

1 reference

1 November 2002

1 reference

European Journal of Cancer

30 November 2017

published in

1 reference

30 November 2017

volume

38 Suppl 6

1 reference

30 November 2017

page(s)

S52-4

1 reference

The third-generation non-steroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer

30 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900285-X

7 January 2021

Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900285-X

7 January 2021

Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900285-X

7 January 2021

Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900285-X

7 January 2021

10.1016/S0959-8049(02)00285-X

Identifiers

DOI

1 reference

30 November 2017

1 reference